Physician profile
Norman Friedman
NPI 1093751398
$34,519.56
in general payments reported to CMS, 2019-2025
67 companies · $385 in 2025
The $385 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,267 · 2020: $3,317 · 2021: $4,013 · 2022: $7,522 · 2023: $6,022 · 2024: $11K · 2025: $385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,977 · Consulting Fee: $7,150 · Travel and Lodging: $959 · Education: $315.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,976.95 |
| Consulting Fee | $7,150.00 |
| Travel and Lodging | $958.92 |
| Education | $314.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $8,580.73 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Abbvie INC. | $4,908.04 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $1,371.04 | 2019-2024 | Austedo Xr, Austedo, Ajovy |
| Alexion Pharmaceuticals, INC. | $1,291.69 | 2019-2024 | Ultomiris, Soliris |
| Supernus Pharmaceuticals, INC. | $1,286.04 | 2019-2023 | |
| Sk Life Science, INC. | $1,077.62 | 2020-2024 | |
| Emd Serono, INC. | $1,049.79 | 2019-2025 | Mavenclad |
| Novartis Pharmaceuticals Corporation | $1,038.70 | 2019-2022 | |
| Biogen, INC. | $979.91 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Ucb, INC. | $954.97 | 2019-2024 | Nayzilam, Fintepla, Zilbrysq |
| Amgen INC. | $787.28 | 2019-2024 | Aimovig, Uplizna |
| Lilly USA, LLC | $774.33 | 2019-2025 | Reyvow, Emgality, Amyvid |
| Jazz Pharmaceuticals INC. | $735.60 | 2019-2024 | |
| Lundbeck LLC | $609.07 | 2019-2024 | Vyepti, Rexulti |
| Harmony Biosciences LLC | $577.12 | 2020-2025 | Wakix |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Norman Friedman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.